Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
information fournie par Boursorama CP 13/10/2025 à 08:30
Ajouter Boursorama à vos sources

Poster presentation on BT-001 in combination with pembrolizumab has shown tumor shrinkage in both injected and non-injected lesions

Strasbourg, France, and Lund, Sweden, October 13, 2025, 8:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, will jointly present a poster on translational data and updated clinical results from the Phase I study of BT-001 at the upcoming European Society for Medical Oncology (ESMO) Annual Meeting. ESMO will take place in Berlin, Germany, from October 17 to 21, 2025.

.../...

Valeurs associées

TRANSGENE
0,8510 EUR Euronext Paris -0,47%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
HAFFNER ENERGY
0,642 +21,59%
Pétrole Brent
99,41 -0,61%
CAC 40
8 171,78 +0,40%
VUSION
132,6 +13,33%
SOITEC
155 +0,10%
Chargement...

Pages les plus populaires

L'offre BoursoBank